{"id":"W4220884345","doi":"10.1158/1538-7445.sabcs21-p5-16-11","title":"Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Palbociclib; Medicine; Breast cancer; Fulvestrant; Internal medicine; Cancer; Oncology; Aromatase inhibitor; Tamoxifen; Pharmacology; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006762487,0.0004251185,0.0006558651,0.0006164185,0.0003678636,0.00004867589,0.0002768319,0.000103674,0.0006367594],"category_scores_gemma":[0.00004728412,0.0003603898,0.00004322584,0.001849209,0.0006563797,0.0005706508,0.0001824509,0.001543823,0.000005289515],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003932191,"about_ca_system_score_gemma":0.0009246245,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01433884,"about_ca_topic_score_gemma":0.01243517,"domain_scores_codex":[0.9954355,0.0003496278,0.0004908787,0.001007777,0.001652415,0.001063747],"domain_scores_gemma":[0.9980811,0.0002634423,0.0002146046,0.0004512776,0.000668954,0.0003205682],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06312507,0.002559861,0.7437544,0.000419018,0.0003097127,0.0002438828,0.01007415,0.001855629,0.01087963,0.0001420339,0.0004082926,0.1662282],"study_design_scores_gemma":[0.02484057,0.002686047,0.9621621,0.001042171,0.00002913723,0.00002880354,0.004326403,0.00004129369,0.00317864,0.0002074161,0.0009705764,0.00048678],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918811,0.001427876,0.00001408775,0.002729377,0.00008083969,0.002497995,0.001116025,0.00004869995,0.0002040234],"genre_scores_gemma":[0.9952004,0.0007129211,0.0001991868,0.0002340514,0.00007357278,0.00297165,0.0002721314,0.0001166229,0.0002194486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2184077,"threshold_uncertainty_score":0.9998915,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0217633982836299,"score_gpt":0.333341173949691,"score_spread":0.3115777756660611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}